Analyzing Acerus Pharmaceuticals (OTCMKTS:ASPCF) and OS Therapies (NYSE:OSTX)

Acerus Pharmaceuticals (OTCMKTS:ASPCF) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Profitability

This table compares Acerus Pharmaceuticals and OS Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%
OS Therapies	N/A	N/A	-569.57%

Earnings and Valuation

This table compares Acerus Pharmaceuticals and OS Therapies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06
OS Therapies	N/A	N/A	-$7.79 million	($0.86)	-1.95

OS Therapies has lower revenue, but higher earnings than Acerus Pharmaceuticals. OS Therapies is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Acerus Pharmaceuticals and OS Therapies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acerus Pharmaceuticals	0	0	0	0	0.00
OS Therapies	0	0	3	2	3.40

OS Therapies has a consensus target price of $18.00, indicating a potential upside of 971.43%. Given OS Therapies’ stronger consensus rating and higher probable upside, analysts clearly believe OS Therapies is more favorable than Acerus Pharmaceuticals.

Summary

OS Therapies beats Acerus Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.